Effects of Yiqi Yangyin Jiedu Formula on advanced non-small cell lung cancer related immune indexes and serum sB7-H3
|更新时间:2022-08-31
|
Effects of Yiqi Yangyin Jiedu Formula on advanced non-small cell lung cancer related immune indexes and serum sB7-H3
Shanghai Journal of Traditional Chinese MedicineVol. 51, Issue 4, Pages: 53-56(2017)
作者机构:
1. 上海中医药大学附属龙华医院肿瘤科,上海,200032
作者简介:
基金信息:
DOI:
CLC:
扫 描 看 全 文
XU Wei-jie, LIU Jia-xiang, ZHAO Li-hong, et al. Effects of Yiqi Yangyin Jiedu Formula on advanced non-small cell lung cancer related immune indexes and serum sB7-H3. [J]. Shanghai Journal of Traditional Chinese Medicine 51(4):53-56(2017)
DOI:
XU Wei-jie, LIU Jia-xiang, ZHAO Li-hong, et al. Effects of Yiqi Yangyin Jiedu Formula on advanced non-small cell lung cancer related immune indexes and serum sB7-H3. [J]. Shanghai Journal of Traditional Chinese Medicine 51(4):53-56(2017)DOI:
Effects of Yiqi Yangyin Jiedu Formula on advanced non-small cell lung cancer related immune indexes and serum sB7-H3
Objective:To observe the effects of Yiqi Yangyin Jiedu Formula on advanced non-small cell lung cancer related immune indexes and serum sB7-H3,and explore the related mechanism based on the influence of costimulatory molecules on T lymphocyte immune response. Methods 60 patients with advanced non-small cell lung cancer who identified as the pattern of qi-yin deficiency in traditional Chinese medicine(TCM) syndrome differentiation were randomly divided into the treatment group and control group,30 cases in each group. The control group was only treated with chemotherapy,the treatment group was treated with Yiqi Yangyin Jiedu Formula additionally based on the treatment for the control group. All the treatments were given with a course of two cycles and one cycle was 21 days. The scores of TCM syndrome and eastern cooperative oncology group performance status(ECOGPS)were observed,and the levels of immune indexes(CD3,+,CD4,+,CD8,+,IL-2)and serum soluble costimulatory molecules sB7-H3 were detected and compared. Results: ①For the comparison between the treatment before and after,the differences on the each and total score of TCM syndrome in the treatment group were all statistically significant(P,<,0.05),the differences on the single score of cough,expectoration,chest tightness,dry mouth and the total score of syndrome in the control group were statistically significant(P,<,0.05). For the comparison after treatment,there were statistically significant differences on the single score of chest pain,fatigue,anorexia,insomnia and the total score of syndrome between the two groups(P,<,0.05). ②For the comparison between the treatment before and after,the difference on the ECOGPS score in the treatment group was statistically significant(P,<,0.05),but the difference on the ECOGPS score in the control group was not statistically significant(P,>,0.05). For the comparison after treatment,there was statistically significant difference on the ECOGPS score between the two groups(P,<,0.05). ③For the comparison between the treatment before and after,the differences on the levels of IL-2 and sB7-H3 in the treatment group were statistically significant(P,<,0.05),but the differences on the levels of all indexes in the control group were not statistically significant(P,>,0.05). For the comparison after treatment,there were statistically significant differences on the levels of CD4,+,IL-2,sB7-H3 between the two groups(P,<,0.05). Conclusion: Yiqi Yangyin Jiedu Formula can improve the syndrome of qi-yin deficiency in patients with lung cancer,increase the proportion of CD4,+, cells and the level of IL-2,reduce the serum level of sB7-H3.
Propensity score matching analysis of the effect of the Yiqi Yangjing Prescription on the survival prognosis of patients with stage Ⅰ⁃ⅢA lung adenocarcinoma after surgery
Staged rehabilitation treatment strategy of traditional Chinese medicine after non⁃small cell lung cancer surgery
Current status of research on traditional Chinese medicine improving acquired resistance to EGFR⁃TKIs in patients with non⁃small cell lung cancer and analysis of TCM pathogenesis
Xu Zhenye’s experience in treating advanced non⁃small cell lung cancer without gene mutation
Efficacy and safety of Yiqi Yangyin Jiedu regimen plus anlotinib in the treatment of advanced non⁃small cell lung cancer
Related Author
No data
Related Institution
Department of Oncology, Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Department of Integrative Medicine, Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Department of Oncology I, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Institute of Clinical Immunology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine